会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Alkylenediamine derivatives
    • 烷二胺衍生物
    • US5310902A
    • 1994-05-10
    • US741590
    • 1991-08-07
    • Mitsuo MasakiMasaru SatohNaoya MoritohKoichi HashimotoToshiro KamishiroHaruhiko Shinozaki
    • Mitsuo MasakiMasaru SatohNaoya MoritohKoichi HashimotoToshiro KamishiroHaruhiko Shinozaki
    • C07D295/13C07D223/00C07D211/26
    • C07D295/13
    • Novel alkylenediamine derivatives effectively employable glutamate blockers have the formula (I) or (II): ##STR1## wherein each of R.sup.1 and R.sup.6 is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aryl group, or an aralkyl group; each of R.sup.2 and R.sup.7 is an aliphatic hydrocarbon group, an alkoxy group, an aliphatic hydrocarbon group containing an ester bonding, an aliphatic hydrocarbon group containing an ether bonding, or an aryloxy group; each of R.sup.3, R.sup.4, R.sup.5 R.sup.8, R.sup.9 and R.sup.10 is hydrogen, an alkyl group, an alkoxy group, an acyloxy group, an aryl group, an aralkyl group, hydroxyl, a hydroxylalkyl group, halogen, nitrile, nitro, amino, carbamoyl or alkoxycarbonyl; and each of m and n is an integer of 0-3 (m+n does not exceed 3); k is an integer of 1-4; each of p and i is an integer of 2-13; and each of q and j is an integer of 4-7.
    • 新型亚烷基二胺衍生物有效地可用的谷氨酸盐阻滞剂具有式(I)或(II):其中R 1和R 6各自为脂族烃基,脂环族烃基,芳基 ,或芳烷基; R 2和R 7各自为脂族烃基,烷氧基,含酯键的脂族烃基,含有醚键的脂族烃基或芳氧基; R 3,R 4,R 5,R 9和R 10各自为氢,烷基,烷氧基,酰氧基,芳基,芳烷基,羟基,羟基烷基,卤素,腈,硝基,氨基,氨基甲酰基 或烷氧基羰基; 并且m和n分别为0-3的整数(m + n不超过3); k是1-4的整数; p和i中的每一个是2-13的整数; 并且q和j中的每一个是4-7的整数。
    • 2. 发明授权
    • Alkylenediamine derivatives
    • 烷二胺衍生物
    • US5070196A
    • 1991-12-03
    • US562422
    • 1990-08-01
    • Mitsuo MasakiMasaru SatohNaoya MoritohKoichi HashimotoToshiro KamishiroHaruhiko Shinozaki
    • Mitsuo MasakiMasaru SatohNaoya MoritohKoichi HashimotoToshiro KamishiroHaruhiko Shinozaki
    • C07D295/13
    • C07D295/13
    • Novel alkylenediamine derivatives effectively employable as glutamate blockers have the formula (I) or (II): ##STR1## wherein each of R.sup.1 and R.sup.6 is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aryl group, or an aralkyl group; each of R.sup.2 and R.sup.7 is an aliphatic hydrocarbon group, an alkoxy group, an aliphatic hydrocarbon group containing an ester bonding, an aliphatic hydrocarbon group containing an ether bonding, or an aryloxy group; each of R.sup.3, R.sup.4, R.sup.5, R.sup.8, R.sup.9 and R.sup.10 is hydrogen, an alkyl group, an alkoxy group, an acyloxy group, an aryl group, an aralkyl group, hydroxyl, a hydroxylalkyl group, halogen, nitrile, nitro, amino, carbamoyl or alkoxycarbonyl; and each of m and n is an integer of 0-3 (m+n does not exceed 3); k is an integer of 1-4; each of p and i is an integer of 2-13; and each of q and j is an integer of 4-7.
    • 作为谷氨酸盐阻滞剂有效利用的新型亚烷基二胺衍生物具有式(I)或(II):其中R 1和R 6各自为脂族烃基,脂环族烃基,芳基 基团或芳烷基; R 2和R 7各自为脂族烃基,烷氧基,含酯键的脂族烃基,含有醚键的脂族烃基或芳氧基; R 3,R 4,R 5,R 8,R 9和R 10各自为氢,烷基,烷氧基,酰氧基,芳基,芳烷基,羟基,羟烷基,卤素,腈,硝基,氨基, 氨基甲酰基或烷氧基羰基; 并且m和n分别为0-3的整数(m + n不超过3); k是1-4的整数; p和i中的每一个是2-13的整数; 并且q和j中的每一个是4-7的整数。
    • 9. 发明授权
    • Method of reducing blood pressure
    • 降低血压的方法
    • US5523317A
    • 1996-06-04
    • US188446
    • 1994-01-26
    • Mitsuo MasakiFumiyo HaraToshiro Kamishiro
    • Mitsuo MasakiFumiyo HaraToshiro Kamishiro
    • A61K31/415A61K31/47A01N43/50
    • A61K31/47A61K31/415
    • Disclosed is a method of reducing blood pressure which comprises administering to a patient an imidazole derivative of the formula: ##STR1## wherein: each of R.sup.1 and R.sup.2 is hydrogen, substituted or unsubstituted alkyl, alkoxyalkyl, cycloalkyl, aryl, aralkyl, or R.sup.1 and R.sup.2 are combined to form hetero ring; each of R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is hydrogen, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, aryl, aryloxy, alkoxycarbonyl, nitro, amino, acyl, or R.sup.3 is combined with R.sup.2 to form heteroring; R.sup.7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylcarbonyl, or S-containing heteroring; each of R.sup.8 and R.sup.9 is hydrogen, halogen, substituted or unsubstituted alkoxy, unsubstituted or substituted alkyl, alkoxycarbonyl, aralkyl, nitro, amino, acyl, substituted or unsubstituted aryl, or R.sup.8 and R.sup.9 are combined to from alkylene; and n is 0 or 1.
    • 公开了降低血压的方法,其包括向患者施用下式的咪唑衍生物:其中:R 1和R 2各自为氢,取代或未取代的烷基,烷氧基烷基,环烷基,芳基,芳烷基, 或R 1和R 2结合形成杂环; R 3,R 4,R 5和R 6中的每一个为氢,卤素,取代或未取代的烷氧基,取代或未取代的烷基,芳基,芳氧基,烷氧基羰基,硝基,氨基,酰基或R3与R 2结合形成杂环; R 7是氢,取代或未取代的烷基,取代或未取代的芳基,取代或未取代的芳基羰基或含S的杂环; R8和R9各自为氢,卤素,取代或未取代的烷氧基,未取代或取代的烷基,烷氧基羰基,芳烷基,硝基,氨基,酰基,取代或未取代的芳基,或R8和R9与亚烷基结合; n为0或1。